Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

Articles

Pharma Pulse 2/27/25: The Threat of Misinformation on Public Health, Congress Turns Attention to PBM Reform, Sort of & more

. He can be reached at nsaraceno@mjhlifesciences.com.

The presidential action follows up on a 2019 final rule aimed at empowering patients and boosting competition among hospitals, group health plans, and health insurance issuers in both individual and group markets.

Trump Signs Healthcare Price Transparency Executive Order

Videos

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, outlines how the tax on goods coming from China and potential 25% tariff on pharmaceuticals could influence generic drug prices. 

Impact of Tariffs on the Generic Drug Market

The latest news for pharma industry insiders.

Pharma Pulse 2/26/25: From Oral Medication to Liquid, FDA Accepts NDA for Epioxa Eye Therapy & more

Patients who utilize the self-pay pharmacy will also be receiving savings on select sizes.

Lilly Adds New Zepbound Vial Doses to the Mix

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, comments on why he believes polypharmacy is an overlooked driver of unnecessary spending and adverse health outcomes.

A Side Effect Cascade

Pharma Pulse 2/25/25: Social Media Influence on Young Women's Reproductive Decisions, Molecular COVID/Flu Multiplex Test Granted FDA Emergency Use & more

The injection for the treatment of psoriatic arthritis—among other indications—is a biosimilar to Stelara. 

Selardsi Launches in the US Market

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, explains the concept of polypharmacy, including how prominent it is in the United States today.

Featured Content

Pharmaceutical Commerce - August 2025

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs